TP53 and ovarian serous adenocarcinoma: Furthermore, these results may facilitate research in serous ovarian cancer, in which the TP53 mutation frequency is reported to be near 90% and for which there are number of interventional clinical studies studying the link between TP53 mutation status and treatment response.